Androgen deprivation therapy remains a critical component of treatment for men with
advanced prostate cancer, and data support its use in metastatic disease and in conjunction …

Due to increasing life expectancy and the introduction of prostate-specific antigen (PSA)
screening, a rising number of elderly men are diagnosed with prostate cancer. Besides PSA …

Background Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation
after radiotherapy may improve quality of life and delay hormone resistance. We assessed …

Androgen deprivation therapy (ADT) is considered as the standard therapy for men with de
novo or recurrent metastatic prostate cancer. ADT commonly leads to initial biochemical and …

Introduction: Drugs are estimated to cause about 10–25% of all cases of gynecomastia. Over
the course of several decades, multiple medications have been implicated in the …

Introduction Because of improved prostate cancer detection, more patients begin androgen
deprivation therapy (ADT) earlier and remain on it longer than before. Patients now may be …

Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …

Background Prostate cancer is the most common cancer in older men in the United States
(USA) and Western Europe. Androgen deprivation (AD) constitutes, in most cases, the first …

Gynecomastia is caused by drugs in 10–25% of all cases. The pathophysiologic mechanism
for some drugs includes exogenous estrogens exposure, medications that cause …

Gonadotropin-releasing hormone agonists (GnRH) play an important role in the treatment of
prostate cancer, improving significantly overall survival. GnRH agonists belong to androgen …